Also known as: Sarpogrelate Base; MCI-9042
Sarpogrelate is a selective 5-HT2A (serotonin) receptor antagonist with potent antiplatelet and vasodilatory activity. Mediocon Inc supplies pharmaceutical-grade Sarpogrelate conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.
Sarpogrelate inhibits serotonin-mediated platelet aggregation and vasoconstriction. It is used clinically in Japan and other Asian markets for the treatment of chronic arterial occlusion and peripheral vascular disease.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2025 |
| Exp Date | FEB 2030 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Sarpogrelate (CAS 941678-49-5) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Sarpogrelate is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance